We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aclaris Therapeutics Inc | NASDAQ:ACRS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -6.11% | 1.23 | 1.26 | 1.38 | 1.36 | 1.28 | 1.30 | 736,993 | 00:07:54 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Monahan Joseph |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Scientific Officer / | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 57132 | D | |
Common Stock | 193 | I | By Spouse |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Buy) | (1) | 8/31/2027 | Common Stock | 56000 | $25.80 | D | |
Employee Stock Option (Right to Buy) | (2) | 1/31/2028 | Common Stock | 14700 | $22.09 | D | |
Restricted Stock Units | (3) | (3) | Common Stock | 2333 | (4) | D | |
Restricted Stock Units | (5) | (5) | Common Stock | 1050 | (4) | D | |
Restricted Stock Units | (6) | (6) | Common Stock | 27500 | (4) | D | |
Restricted Stock Units | (7) | (7) | Common Stock | 50000 | (4) | D | |
Restricted Stock Units | (8) | (8) | Common Stock | 37500 | (4) | D | |
Restricted Stock Units | (9) | (9) | Common Stock | 200000 | (4) | D |
Remarks: Exhibit 24.1 - Power of Attorney |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Monahan Joseph C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE, PA 19087 | Chief Scientific Officer |
Signatures | ||
/s/ Mark Ballantyne, as Attorney-in-Fact | 5/17/2021 | |
**Signature of Reporting Person | Date |
1 Year Aclaris Therapeutics Chart |
1 Month Aclaris Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions